264 related articles for article (PubMed ID: 25238223)
1. Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia.
Skoumas J; Liontou C; Chrysohoou C; Masoura C; Aznaouridis K; Pitsavos C; Stefanadis C
Atherosclerosis; 2014 Nov; 237(1):140-5. PubMed ID: 25238223
[TBL] [Abstract][Full Text] [Related]
2. Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up.
Skoumas I; Ioakeimidis N; Vlachopoulos C; Chrysohoou C; Michalakeas C; Georgakopoulos C; Katsi V; Panagiotakos D; Tousoulis D
Angiology; 2018 Mar; 69(3):242-248. PubMed ID: 28681648
[TBL] [Abstract][Full Text] [Related]
3. Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia.
Skoumas I; Masoura C; Pitsavos C; Tousoulis D; Papadimitriou L; Aznaouridis K; Chrysohoou C; Giotsas N; Toutouza M; Tentolouris C; Antoniades C; Stefanadis C
Int J Cardiol; 2007 Oct; 121(2):178-83. PubMed ID: 17188767
[TBL] [Abstract][Full Text] [Related]
4. Statin-associated incident diabetes: a literature review.
Park ZH; Juska A; Dyakov D; Patel RV
Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
Lupattelli G; Siepi D; De Vuono S; Roscini AR; Crisanti F; Covelli D; Pirro M; Mannarino E
Life Sci; 2012 Jun; 90(21-22):846-50. PubMed ID: 22554491
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia.
Skoumas J; Papadimitriou L; Pitsavos C; Masoura C; Giotsas N; Chrysohoou C; Toutouza M; Panagiotakos D; Stefanadis C
Metabolism; 2007 Jan; 56(1):135-41. PubMed ID: 17161236
[TBL] [Abstract][Full Text] [Related]
7. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Cho Y; Choe E; Lee YH; Seo JW; Choi Y; Yun Y; Wang HJ; Ahn CW; Cha BS; Lee HC; Kang ES
Metabolism; 2015 Apr; 64(4):482-8. PubMed ID: 25312577
[TBL] [Abstract][Full Text] [Related]
8. [STATINS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE AND DIABETES INCIDENCE--THE BENEFITS VERSUS THE RISKS].
Lavie G; Cohen S
Harefuah; 2015 Jun; 154(6):382-6, 404. PubMed ID: 26281083
[TBL] [Abstract][Full Text] [Related]
9. Risk of new-onset diabetes among patients treated with statins according to hypertension and gender: Results from a nationwide health-screening cohort.
Lee SE; Sung JM; Cho IJ; Kim HC; Chang HJ
PLoS One; 2018; 13(4):e0195459. PubMed ID: 29630642
[TBL] [Abstract][Full Text] [Related]
10. Vascular inflammation and metabolic activity in hematopoietic organs and liver in familial combined hyperlipidemia and heterozygous familial hypercholesterolemia.
Toutouzas K; Skoumas J; Koutagiar I; Benetos G; Pianou N; Georgakopoulos A; Galanakos S; Antonopoulos A; Drakopoulou M; Oikonomou EK; Kafouris P; Athanasiadis E; Metaxas M; Spyrou G; Pallantza Z; Galiatsatos N; Aggeli C; Antoniades C; Keramida G; Peters AM; Anagnostopoulos CD; Tousoulis D
J Clin Lipidol; 2018; 12(1):33-43. PubMed ID: 29174439
[TBL] [Abstract][Full Text] [Related]
11. Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels.
Cho Y; Lee MJ; Choe EY; Jung CH; Joo DJ; Kim MS; Cha BS; Park JY; Kang ES
Liver Transpl; 2014 May; 20(5):557-63. PubMed ID: 24477986
[TBL] [Abstract][Full Text] [Related]
12. [Familial combined hyperlipidemia: consensus document].
Mata P; Alonso R; Ruíz-Garcia A; Díaz-Díaz JL; González N; Gijón-Conde T; Martínez-Faedo C; Morón I; Arranz E; Aguado R; Argueso R; Perez de Isla L
Semergen; 2014 Oct; 40(7):374-80. PubMed ID: 25131181
[TBL] [Abstract][Full Text] [Related]
13. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
14. The effect of diabetes, hyperlipidemia, and statins on the development of rotator cuff disease: a nationwide, 11-year, longitudinal, population-based follow-up study.
Lin TT; Lin CH; Chang CL; Chi CH; Chang ST; Sheu WH
Am J Sports Med; 2015 Sep; 43(9):2126-32. PubMed ID: 26085191
[TBL] [Abstract][Full Text] [Related]
15. Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular disease.
van de Woestijne AP; van der Graaf Y; Westerink J; Nathoe HM; Visseren FL
Am J Cardiol; 2015 Feb; 115(4):441-6. PubMed ID: 25554536
[TBL] [Abstract][Full Text] [Related]
16. Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk.
Izzo R; de Simone G; Trimarco V; Giudice R; De Marco M; Di Renzo G; De Luca N; Trimarco B
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1101-6. PubMed ID: 23419735
[TBL] [Abstract][Full Text] [Related]
17. The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients.
Kim TM; Kim H; Jeong YJ; Baik SJ; Yang SJ; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1156-1163. PubMed ID: 28556206
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
19. HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.
Choe EY; Wang HJ; Kwon O; Cho Y; Huh KH; Kim MS; Kim YS; Ahn CW; Cha BS; Lee HC; Kang ES
Transplantation; 2014 Feb; 97(4):419-25. PubMed ID: 24285338
[TBL] [Abstract][Full Text] [Related]
20. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.
Pitsavos C; Skoumas I; Tousoulis D; Metalinos G; Masoura C; Chrysohoou C; Papadimitriou L; Giotsas N; Toutouza M; Antoniades C; Stefanadis C
Int J Cardiol; 2009 May; 134(2):280-1. PubMed ID: 18353459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
